The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC). NAME Vismodegib (Erivedge) and sonidegib (Odomzo)
APPROVED FOR
Locally advanced BCC (vismodegib and sonidegib) and metastatic BCC (vismodegib)
TYPE

Small molecules
MOLECULAR TARGETS
Vismodegib and sonidegib bind to and inhibit Smoothened (SMO), a transmembrane protein involved in Hh pathway signal transduction.
CELLULAR TARGETS
Extracellular Hh ligands bind to the receptor patched (PTCH), alleviating PTCH-mediated inhibition of SMO. Uninhibited SMO signals through several proteins, including SUFU, leading to activation of Gli-mediated gene transcription (e.g., PTCH/GLI, IGF, cyclin D) and cellular proliferation.
EFFECTS ON TARGETS
Inhibition of SMO results in decreased Gli levels, reduction of Glicontrolled transcription, and reduced cellular proliferation.
DEVELOPED BY
Vismodegib | Curis > Genentech/Roche Sonidegib | Novartis 
